Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): An intergroup study of CALGB, COG, ECOG, and SWOG.

被引：0
|
作者：
Flaherty, Lawrence E.
Moon, James
Atkins, Michael B.
Tuthill, Ralph
Thompson, John A.
Vetto, John T.
Haluska, Frank G.
Pappo, Alberto S.
Sosman, Jeffrey Alan
Redman, Bruce G.
Ribas, Antoni
Kirkwood, John M.
Sondak, Vernon K.
机构：
[1] Wayne State Univ, Detroit, MI USA
[2] SW Oncol Grp, Ctr Stat, Seattle, WA USA
[3] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[4] Cleveland Clin, Cleveland, OH 44106 USA
[5] Seattle Canc Care Alliance, Seattle, WA USA
[6] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[7] ARIAD Pharmaceut, Cambridge, MA USA
[8] St Jude Childrens Res Hosp, Memphis, TN 38105 USA
[9] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[10] Univ Michigan, Ann Arbor, MI 48109 USA
[11] Univ Calif Los Angeles, Los Angeles, CA USA
[12] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[13] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8504
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Protein S-100β serum levels predicts clinical outcome of high-risk melanoma patients treated with high-dose adjuvant interferon alfa2b
    Garcia-Albeniz, X.
    Domingo-Domenech, J.
    Auge, J.
    Molina, R.
    Puig, S.
    Malvehy, J.
    Marmol, M.
    Gascon, P.
    Mellado, B.
    Castel, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [32] Phase II randomized study of high-dose interferon alfa-2b (HDI) versus chemotherapy as adjuvant therapy in patients with resected mucosal melanoma
    Lian, Bin
    Mao, Li Li
    Cui, Chuan Liang
    Chi, Zhi Hong
    Si, Lu
    Sheng, Xi Nan
    Li, Si Ming
    Tang, Bi Xia
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609
    McLouth, Laurie E.
    Zheng, Yue
    Smith, Stephanie
    Hodi, F. Stephen
    Rao, Uma N.
    Cohen, Gary, I
    Amatruda, Thomas T.
    Dakhil, Shaker R.
    Curti, Brendan D.
    Nakhoul, Ibrahim
    Chandana, Sreenivasa R.
    Bane, Charles L.
    Marinier, David E.
    Lee, Sandra J.
    Sondak, Vernon K.
    Kirkwood, John M.
    Tarhini, Ahmad A.
    Wagner, Lynne, I
    QUALITY OF LIFE RESEARCH, 2023, 32 (01) : 183 - 196
  • [34] Adjuvant androgen deprivation (ADT) versus mitoxantrone plus prednisone (MP) plus ADT in high-risk prostate cancer (PCa) patients following radical prostatectomy: A phase III intergroup trial (SWOG S9921) NCT00004124.
    Glode, L. Michael
    Tangen, Catherine M.
    Hussain, Maha
    Swanson, Gregory P.
    Wood, David Peter
    Sakr, Wael
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [35] A phase III randomized trial of adjuvant biochemotherapy (BC) versus interferon-α-2b (IFN) in patients (pts) with high risk for melanoma recurrence.
    Kim, K. B.
    Legha, S. S.
    Gonzalez, R.
    Anderson, C.
    Papadopoulos, N. E.
    Eton, O.
    Plager, C.
    Roe, A.
    Liu, P.
    Bedikian, A. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 453S - 453S
  • [36] High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of Intergroup Trial E1690/S9111/C9190
    Kirkwood, JM
    Ibrahim, JG
    Sondak, VK
    Richards, J
    Flaherty, LE
    Ernstoff, MS
    Smith, TJ
    Rao, U
    Steele, M
    Blum, RH
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (12) : 2444 - 2458
  • [37] Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma.
    Grossmann, Kenneth F.
    Othus, Megan
    Patel, Sapna Pradyuman
    Tarhini, Ahmad A.
    Sondak, Vernon K.
    Petrella, Teresa M.
    Truong, Thach-Giao
    Khushalani, Nikhil I.
    Cohen, Justine Vanessa
    Buchbinder, Elizabeth Iannotti
    Kendra, Kari Lynn
    Funchain, Pauline
    Lewis, Karl D.
    Chmielowski, Bartosz
    Li, Hongli
    Moon, James
    Gunturu, Krishna Soujanya
    Eroglu, Zeynep
    Kirkwood, John M.
    Ribas, Antoni
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: An interim analysis of a randomized phase III study (NCT00226408)
    Mohr, P.
    Hauschild, A.
    Enk, A.
    Trefzer, U.
    Rass, K.
    Grabbe, S.
    Brockmeyer, N. H.
    Koller, J.
    Gogas, H.
    Weichenthal, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial
    Hansson, Johan
    Aamdal, Steinar
    Bastholt, Lars
    Brandberg, Yvonne
    Hernberg, Micaela
    Nilsson, Bo
    Stierner, Ulrika
    von der Maase, Hans
    LANCET ONCOLOGY, 2011, 12 (02): : 144 - 152
  • [40] Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Final analysis of a randomized phase III DeCOG-trial (NCT00226408).
    Mohr, Peter
    Hauschild, Axel
    Trefzer, Uwe
    Enk, Alexander
    Tilgen, Wolfgang
    Loquai, Carmen
    Gogas, Helen
    Haalck, Thomas
    Koller, Josef
    Schadendorf, Dirk
    Dummer, Reinhard
    Gutzmer, Ralf
    Brockmeyer, Norbert
    Hoelzle, Erhard
    Sunderkoetter, Cord
    Mauch, Cornelia
    Stein, Anette
    Schneider, Lars
    Podda, Maurizio
    Weichenthal, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345